Newsroom | 57196 results

SAN DIEGO--(BUSINESS WIRE)--WD-40 Company (NASDAQ:WDFC) today announced that its board of directors declared on Wednesday, December 10, 2025, a quarterly dividend of $1.02 per share reflecting an increase of more than 8 percent compared to the previous quarter’s dividend. The quarterly dividend is payable January 30, 2026 to stockholders of record at the close of business on January 16, 2026. The Company also announced that it has scheduled its first quarter 2026 earnings conference call for Th...

STAMFORD, Conn.--(BUSINESS WIRE)--ITT Inc. (NYSE: ITT) today announced the closing of its previously announced underwritten public offering of 8,050,000 shares of its common stock....

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Rayonier Advanced Materials Inc. (NYSE: RYAM) (the “Company”), a global leader of cellulose-based technologies, announced that President and Chief Executive Officer De Lyle W. Bloomquist has informed the Board of Directors of his intention to retire by the time of the Company’s 2026 Annual Meeting of Stockholders, expected in May 2026. Mr. Bloomquist also confirmed he will not stand for re-election to the Company’s Board of Directors. To ensure continuity an...

TEMPE, Ariz.--(BUSINESS WIRE)--Amtech Systems, Inc. ("Amtech") (NASDAQ: ASYS), a manufacturer of equipment and consumables enabling AI semiconductor device packaging and advanced substrate fabrication, today reported results for its fourth quarter ended September 30, 2025. Fourth Quarter Fiscal 2025 Financial and Operational Highlights: Net revenue of $19.8 million Cash of $17.9 million Cash provided by operations of $2.3 million GAAP net income of $1.1 million Non-GAAP net income of $1.4 milli...

DUBLIN--(BUSINESS WIRE)--The "Single-use Bioprocessing Market by Product (Equipment [Bioreactors, Filtration, Chromatography], Consumables [Filters, Bags, Assemblies, Sensors]), Application (Storage, Mixing), Workflow (Upstream), Molecule Type (mAbs, Vaccines) - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering. The global single-use bioprocessing market size is anticipated to reach USD 33.67 billion by 2030, expanding at a CAGR of 13.3% from 2025 to 2030. This impres...

ZUG, Schweiz--(BUSINESS WIRE)--Polpharma Biologics, ein führendes biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Herstellung von Biosimilars spezialisiert hat, freut sich, die Unterzeichnung einer wegweisenden Lizenzvereinbarung mit dem brasilianischen Unternehmen Libbs Farmacêutica bekannt zu geben! Durch diese strategische Partnerschaft erhält Libbs Farmacêutica die Exklusivrechte für die Vermarktung eines hochmodernen Biosimilars für Autoimmunerkrankungen auf dem schnell w...

ZOUG, Suisse--(BUSINESS WIRE)--Polpharma Biologics, une société biopharmaceutique de premier plan spécialisée dans le développement et la fabrication de médicaments biosimilaires, est ravie d’annoncer la signature d’un accord de licence historique avec la société brésilienne Libbs Farmacêutica ! Grâce à ce partenariat stratégique, Libbs Farmacêutica obtiendra les droits exclusifs de commercialisation d’un médicament biosimilaire de pointe pour les maladies auto-immunes sur le marché brésilien e...

ZUG, Suiza--(BUSINESS WIRE)--Polpharma Biologics, una empresa biofarmacéutica líder especializada en el desarrollo y la fabricación de biosimilares, se complace en anunciar la firma de un acuerdo de licencia histórico con la empresa brasileña Libbs Farmacêutica. A través de esta alianza estratégica, Libbs Farmacêutica obtendrá los derechos exclusivos para comercializar un biosimilar de vanguardia para enfermedades autoinmunes en el mercado brasileño, que está experimentando un rápido crecimient...

DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of Smith Excavating, LLC to Enceladus Partners. Headquartered in Winston-Salem, North Carolina, Smith Excavating, LLC is a second-generation, family-owned company specializing in annual right-of-way vegetation management, infrastructure asset repair & maintenance, and industrial site services. With over 20 years of experience, the compa...

ZUGO, Svizzera--(BUSINESS WIRE)--Polpharma Biologics, leader biofarmaceutico specializzato nello sviluppo e nella produzione di biosimilari, annuncia con entusiasmo la sigla di un importante accordo di licenza con la brasiliana Libbs Farmacêutica. Grazie a questa partnership strategica, Libbs Farmacêutica otterrà i diritti esclusivi di commercializzazione relativi a un avanzato biosimilare mirato alle malattie autoimmuni nel mercato brasiliano, in rapida espansione. Polpharma Biologics manterrà...